Intrinsa

a testosterone patch for hypoactive sexual desire disorder for women who had undergone surgical castration via bilateral oophorectomy

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

1.	Psychological Sexual Dysfunctions (Sexual Arousal Disorder) 03/01/2009 - "There is some suggestion of a link between sexual dysfunction in postmenopausal women and low circulating concentrations of testosterone.1 This underlies the development of a new transdermal testosterone patch (black triangle down Intrinsa - Procter & Gamble) that has recently been licensed in the UK for the treatment of women who have hypoactive sexual desire disorder (HSDD) following a menopause induced by surgery (i.e. " 05/01/2005 - "The sexual medicine community watched with interest as the Food and Drug Administration (FDA) considered the Proctor & Gamble new drug application for Intrinsa (a testosterone patch for hypoactive sexual desire disorder for women who had undergone surgical castration via bilateral oophorectomy). " 03/01/2010 - "Intrinsa is a transdermal testosterone patch that is indicated for use in hypoactive sexual desire disorder (HSDD) in women who have undergone bilateral oophorectomy and hysterectomy (surgically-induced menopause) receiving concomitant oestrogen therapy. "
2.	Treatment-Resistant Depressive Disorder 12/01/2009 - "Low-dose transdermal testosterone (300 mcg/day, Intrinsa, Procter and Gamble Pharmaceuticals) was administered to nine women with treatment-resistant depression in an 8 week open-label pilot protocol. "

1.	Testosterone (Sustanon)